Inclusion Criteria:
Inclusion criteria for enrolment
- Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and subjects' Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
- Written informed consent obtained from the subject/LAR(s) of the subject prior to performance of any study-specific procedure.
- Subjects who previously participated in study ZOSTER-041 and completed the full 2 dose HZ/su primary vaccination course.
Inclusion criteria for revaccination
- Subjects receiving maintenance CIS therapy for the prevention of allograft rejection for a minimum of one month prior to the first revaccination.
- Subjects without an episode of allograft rejection within 90 days prior to the first revaccination visit.
- Female subjects of non-childbearing potential may be revaccinated. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause.
- Female subjects of childbearing potential may be revaccinated, if the subject:
has practiced adequate contraception for 30 days prior to revaccination, and
has a negative pregnancy test on the day of revaccination, and
has agreed to continue adequate contraception up to 2 months after completion of the revaccination series.
Exclusion Criteria:
Exclusion criteria for enrolment Medical conditions
- Vaccination against HZ since completion of study ZOSTER-041.
- Significant underlying illness that, in the opinion of the investigator, is expected to prevent completion of the study.
- Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study.
Prior/Concurrent clinical study experience
• Concurrently participating in another interventional vaccine or immunosuppressive clinical study, in which the subject is exposed to an investigational or a non-investigational vaccine/product (drug) at any time during the ZOSTER-073 study.
Exclusion criteria for revaccination Medical conditions
- History of confirmed HZ within one year before revaccination visit (Visit 3).
- More than one organ transplanted.
- Any additional confirmed or suspected immunosuppressive or immunodeficient condition.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
- Any other condition that, in the opinion of the investigator, would interfere with the evaluations required by the study or make vaccination unsafe.
Prior/Concomitant therapy
- Administration or planned administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the first revaccination dose of study vaccine and ending at Visit 5 (Month 26).
- Use of anti-CD20 or other B-cell monoclonal antibody agents as maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months of first revaccination dose of study vaccine.
- Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of maintenance immunosuppressive therapies.
- Planned administration/administration of a live vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study vaccine administration.
- Planned administration/administration of a non-replicating or subunit vaccine, not foreseen by the study protocol, in the period starting 8 days before and ending 30 days after each dose of study vaccine.
Other exclusion criteria for revaccination
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions up to 2 months post-revaccination Dose 2.
- Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.